- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05544162
Personalized Nutrition Delivery to Improve Resilience in Older Adult Trauma Patients (SeND Home)
Personalized Targeted Nutrition Via StructurEd Nutrition Delivery Pathway to Improve Resilience in Older Adult Trauma Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Pilot study designed to set up for an randomized clinical trial (RCT) comparing the SeND Home pathway to a standard of care nutrition delivery in critically ill older adult trauma patients. The SeND Home Pathway supports patients from ICU admission to 2-weeks post-hospital discharge, providing a comprehensive and personalized plan of care carried to completion.
Subjects will be randomized 3:1 to either SeND Home precision nutrition pathway or control arm. Subjects randomized to the SeND Home arm will receive oral nutrition supplements (Ensure shakes) up to 3 times per day while in the hospital and for 4 weeks after discharge. Some subjects in this arm will be asked to participate in an interview after being discharged from the hospital. Subjects in the standard of care arm will receive normal nutrition recommendations from their clinical providers.
Participants in both groups will undergo non-invasive tests that measure how much energy (calories) they are using, body composition, and muscle mass. They will also be asked to complete walking and strength tests, and surveys about quality of life.These will be done every 3-7 days during hospitalization, at hospital discharge, and at a 3 month post-discharge follow-up visit.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who are at least 60 years old and admitted to the trauma service
- Patients who have had a standard of care CT scan
Exclusion Criteria:
- Expected withdrawal of life-sustaining treatment within 48 hours
- Prisoners
- Unable to provide informed consent
- Non-English speakers
- Traumatic Brain Injury
- Allergic to milk or soy ingredients (Common allergen in Ensure shakes).
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control pathway
Standard of care nutrition delivery throughout hospitalization.
Upon discharge they will be sent home with standard nutrition information without Indirect Calorimetry (IC) guidance.
|
|
|
Experimental: SeND Home precision nutrition pathway
Oral nutrition supplements (ONS) will be given, at maximum, three times per day throughout hospitalization.
Upon discharge, participants will be given 4-weeks' worth of oral supplements to take.
Adjustments may be made based on indirect calorimetry (IC) measurements by the clinical dietitian.
|
Ensure shakes will be take up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients Recruited
Time Frame: Baseline
|
This outcome is a measure of feasibility of the SeND Home pathway
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Study Participants Who Adhere to the SeND Home Treatment Protocol
Time Frame: approximately 98 days
|
This outcome is a measure of feasibility of the SeND Home pathway
|
approximately 98 days
|
|
Percentage of Participants Retained to Study Completion
Time Frame: hospital stay plus 90 days
|
This outcome is a measure of feasibility of the SeND Home pathway
|
hospital stay plus 90 days
|
|
Time to Complete Each Outcome
Time Frame: 3 months
|
This outcome is an assessment of feasibility (participant burden)
|
3 months
|
|
How Well Outcome Assessments Are Tolerated
Time Frame: 3 months
|
This outcome is an assessment of feasibility (participant burden)
|
3 months
|
|
Duration of Testing Time
Time Frame: 3 months
|
This outcome is an assessment of feasibility (participant burden)
|
3 months
|
|
Ability to Successfully Complete Testing in One Cycle Will be Recorded
Time Frame: 3 months
|
This outcome is an assessment of feasibility (participant burden)
|
3 months
|
|
Provider Satisfaction With SeND Home
Time Frame: 18 months
|
This outcome is a measure of acceptability and will be used to iteratively adapt the SeND home design as progress throughout the study
|
18 months
|
|
Provider Assessment of Usefulness of SeND Home
Time Frame: 18 months
|
This outcome is a measure of acceptability and will be used to iteratively adapt the SeND home design as progress throughout the study
|
18 months
|
|
Number of Interventions Delivered Per Protocol in the ICU, on the Floor, and In-home
Time Frame: 18 months
|
The outcome is a measure of the fidelity of SeND Home
|
18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Krista Haines, MD, Duke University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00110867
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Illness
-
Duke UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Not yet recruitingDecision Making | Neonatal Critical Illness | Pediatric Critical IllnessUnited States
-
Duke UniversityNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedNeonatal Critical Illness | Pediatric Critical IllnessUnited States
-
Istituto Clinico HumanitasRecruitingCritical Illness Myopathy | Critical Illness Polyneuropathy | Critical Illness PolyneuromyopathyItaly
-
Assistance Publique - Hôpitaux de ParisEuropean Society of Intensive Care Medicine; French Society for Intensive Care and other collaboratorsRecruitingCritical Illness | Intensive Care Patients | Critical Illness Requiring Intensive Care - Sepsis | Critical Illness Requiring Intensive Care - Acute Brain Injury | Critical Illness Requiring Intensive Care - Major Surgery | Critical Illness Requiring Intensive Care - PolytraumaFrance
-
Boston Children's HospitalCompleted
-
Karolinska InstitutetNot yet recruitingPediatric Critical IllnessSweden
-
McMaster UniversityLondon Health Sciences Centre; McMaster Children's Hospital; Canadian Critical...CompletedPediatric Critical IllnessCanada
-
Sándor BeniczkyUniversity of Aarhus; Danish Council for Independent Research; Søster og Verner...CompletedCritical Illness Myopathy | Myopathy Critical IllnessDenmark
-
Istanbul Medeniyet UniversityRecruiting
-
St Helens & Knowsley Teaching Hospitals NHS TrustManchester University NHS Foundation TrustCompleted
Clinical Trials on Nutrition supplement - Ensure shakes
-
NYU Langone HealthRecruitingInflammatory Bowel DiseasesUnited States
-
Duke UniversityUnited States Department of Defense; Baxter Healthcare CorporationRecruiting
-
PharmanexNu Skin EnterprisesCompletedSafety/EffacyUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnClinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Esophageal Adenocarcinoma... and other conditionsUnited States
-
Boston Medical CenterAbbott; Vascular & Endovascular Surgery SocietyRecruitingMalnutrition | Critical Limb Ischemia | Nutritional SupplementsUnited States
-
The First Affiliated Hospital with Nanjing Medical...CompletedMalnutrition Risk in ElderChina
-
Singapore General HospitalAbbottWithdrawn
-
Ningbo No. 1 HospitalUnknown
-
Meshalkin Research Institute of Pathology of CirculationTerminated
-
Wake Forest University Health SciencesWithdrawnMuscle Weakness | ICU-acquired WeaknessUnited States